Fact CheckerSign in

NCT07279116Not yet recruitingPhase 1

ABY-029 Head & Neck Trial

Phase 1 Trial of ABY-029 Fluorescence in Patients With Head and Neck Squamous Cell Carcinoma

Source: ClinicalTrials.gov · Last updated 7 May 2026

Brief summary (registry, in English)

The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach head and neck squamous cell carcinomas (HNSCC) so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
24 (estimated)
First submitted
8 Dec 2025
Start date
30 Jun 2026
Primary completion date
31 Dec 2027
Lead sponsor
Dartmouth-Hitchcock Medical Center
NCT number
NCT07279116

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 24
  • From 30 Jun 2026 to the primary completion date, 31 Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients with a medical history of (Grade 2 or higher) hepatic/renal function compromise.

Lab values

  • Patients on experimental or approved anti-EGFR targeted therapies.

Other

  • Prisoners
  • Individuals who are pregnant or breast feeding.

Who the study is looking for

  • Preoperative diagnosis of head and neck squamous cell carcinoma with planned surgical resection of the oral cavity, oropharynx, larynx, or hypopharynx.
  • Tumor judged to be operable.
  • Valid informed consent by participant.
  • Age ≥ 18 years old.
  • Ability to understand and the willingness to sign a written informed consent document.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.